Synthesis of 6-oxy functionalized campest-4-en-3-ones: efficient hydroperoxidation at C-6 of campest-5-en-3-one with molecular oxygen and silica gel
摘要:
As a reference compound library for the investigation of biosynthesis of brassinosteroids, focused on a pathway from campesterol (1) to campestanol (2), 6-oxy functionalized campest-4-en-3-ones as well as campest-5-en-3-one (7) and campestane-3,6-dione were prepared from 1. Oxidation of 1 with pyridinium chlorochromate buffered by calcium carbonate gave 5-en-3-one (7) in 76% yield. Treatment of 7 with silica gel under an oxygen atmosphere in ethyl ether at room temperature produced efficient hydroperoxidation at the C-6 position to give 6 alpha-hydroperoxycampest-4-en-3-one and 6 beta-hydroperoxycampest-4-en-3-one in 34% and 49% yields, respectively. These compounds were converted to 6 alpha-hydroxycampest-4-en-3-one and 6 beta-hydroxycampest-4-en-3-one by reduction with triethyl phosphite. This provided the first example of the practical use of hydroperoxidation at C-6 of a Delta(5(6))-unsaturated 3-oxo-steroid with molecular oxygen and silica gel. On the other hand, oxidation of 1 with pyridinium chlorochromate in the absence of calcium carbonate gave campest-4-ene-3,6-dione in 64% yield. This compound was then converted in a highly stereoselective manner to campestane-3,6-dione with A/B trans ring junction by reduction with titanium (III) chloride in 85% yield.
Synthesis of 6-oxy functionalized campest-4-en-3-ones: efficient hydroperoxidation at C-6 of campest-5-en-3-one with molecular oxygen and silica gel
摘要:
As a reference compound library for the investigation of biosynthesis of brassinosteroids, focused on a pathway from campesterol (1) to campestanol (2), 6-oxy functionalized campest-4-en-3-ones as well as campest-5-en-3-one (7) and campestane-3,6-dione were prepared from 1. Oxidation of 1 with pyridinium chlorochromate buffered by calcium carbonate gave 5-en-3-one (7) in 76% yield. Treatment of 7 with silica gel under an oxygen atmosphere in ethyl ether at room temperature produced efficient hydroperoxidation at the C-6 position to give 6 alpha-hydroperoxycampest-4-en-3-one and 6 beta-hydroperoxycampest-4-en-3-one in 34% and 49% yields, respectively. These compounds were converted to 6 alpha-hydroxycampest-4-en-3-one and 6 beta-hydroxycampest-4-en-3-one by reduction with triethyl phosphite. This provided the first example of the practical use of hydroperoxidation at C-6 of a Delta(5(6))-unsaturated 3-oxo-steroid with molecular oxygen and silica gel. On the other hand, oxidation of 1 with pyridinium chlorochromate in the absence of calcium carbonate gave campest-4-ene-3,6-dione in 64% yield. This compound was then converted in a highly stereoselective manner to campestane-3,6-dione with A/B trans ring junction by reduction with titanium (III) chloride in 85% yield.
A hypoglycemic agent comprising a compound selected from the group consisting of 24-alkylcholestan-3-ones and 24-alkylcholesten-3-ones (for example, 24-alkylcholestan-3-ones, 24-alkylcholestmonoen-3-ones, 24-alkylcholestdien-3-ones, 24-alkylcholesttrien-3-ones, or 24-alkylcholesttetraen-3-ones, preferably 5-campesten-3-one) as an active ingredient. The agent can be used for improvement of hyperglycemia resulting from diseases such as diabetes, and can be used as a safe medicament without side effects such as hypoglycemia or diarrhea.
DRUGS, FOOD OR DRINK FOR IMPROVING PANCREATIC FUNCTIONS
申请人:MORINAGA MILK INDUSTRY CO., LTD.
公开号:EP1808175A1
公开(公告)日:2007-07-18
Compounds such as 4-methylcholest-7-en-3-ol, 4-methylergost-7-en-3-ol and 4-methylstigmast-7-en-3-ol which have an activity for improving pancreatic function are used as an active ingredient of a pancreas function improving drug and food or drink.
According to the present invention, a transdermal absorbent for reducing a subcutaneous fat is provided, which comprises phytostenone. Accordingly, a method for further reducing a subcutaneous fat can be provided.
Medicament for treating obesity and improving lipid metabolism
申请人:RIKEN
公开号:US20020086855A1
公开(公告)日:2002-07-04
A medicament for preventive and therapeutic treatment of obesity and a disease with abnormal lipid metabolism which comprises a 24-alkylcholest-5-en-3-one as an active ingredient.
一种用于预防和治疗肥胖症和脂质代谢异常疾病的药物,其活性成分为 24-烷基胆甾-5-烯-3-酮。
DAS5, a P450 protein involved in the brassinosteroid biosynthesis pathway in plants
申请人:——
公开号:US20030150025A1
公开(公告)日:2003-08-07
The present invention provides a cytochrome P450-encoding gene, DAS5, as well as an altered gene, das5-D, which are involved in the synthesis of the plant steroid hormone brassinolide. The das5-D mutant has an insertion of a T-DNA containing transcriptional enhancers into its promoter region. Overexpression of the mutant thus produces large amounts of DAS5 transcript. The expression of this das5-D mutation or overexpression of the DAS5 gene in transgenic plants causes such plants to become significantly larger and more robust than their wild-type counterparts, thus increasing plant yields.